Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access program of Tarceva (erlotinib) in advanced stage IIIB/IV non-small cell lung cancer
2004-000564-28Phase 4Completed
- Sponsor
- Roche
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoint: Duration of Tarceva treatment benefit. Started Sep 2004; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-000564-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000564-28.